<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503565</url>
  </required_header>
  <id_info>
    <org_study_id>2018-03-015</org_study_id>
    <nct_id>NCT03503565</nct_id>
  </id_info>
  <brief_title>Intraoperative Neuromuscular Blockade and Postoperative Atelectasis</brief_title>
  <official_title>The Effect of Intraoperative Neuromuscular Blockade on Postoperative Atelectasis in Patients Undergoing Thoracic Surgery With One Lung Ventilation: Moderate vs. Deep Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyung Hee University Hospital at Gangdong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During one-lung ventilation in thoracic surgery, the intensity of neuromuscular blockade may&#xD;
      change the compliance and resistance of ventilated lung, thereby affecting postoperative&#xD;
      atelectasis. The present study investigated the effect of the intensity of intraoperative&#xD;
      neuromuscular blockade on the postoperative atelectasis using chest computerized tomography&#xD;
      in patients receiving thoracic surgery requiring one-lung ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neuromuscular blocking agents can be used to secure a good surgical field, but it can also&#xD;
      cause delayed extubation or postoperative pulmonary complications. Traditionally, rocuronium&#xD;
      which is a commonly used non-depolarizing agent is usually reversed by cholinesterase&#xD;
      inhibitors such as neostigmine or pyridostigmine. These drugs act by increasing the&#xD;
      concentration of acetylcholine at the neuromuscular junction (a competing antagonist), not by&#xD;
      direct antagonists. Consequently, there is a risk of pulmonary complications when&#xD;
      cholinesterase inhibitor is not used appropriately. Use of sugammadex can reverse&#xD;
      neuromuscular blockade (NMB) quickly, thereby being helpful for spontaneous deep breathing&#xD;
      postoperatively. In a previous study, the moderate neuromuscular blockade was not guaranteed&#xD;
      during surgery because intraoperative train-of-four (TOF) monitoring was not used and the&#xD;
      outcome was focused on the correlation between reversal agent and the overall incidence of&#xD;
      postoperative pulmonary complications. However, in the present study, TOF ratio or&#xD;
      post-tetanic count (PTC) was repeatedly measured during surgery, thereby the intensity of&#xD;
      intraoperative NMB being maintained. Moreover, lung compliance was repeatedly measured during&#xD;
      surgery and the correlation between the intensity of intraoperative NMB and postoperative&#xD;
      atelectasis which is evaluated by quantitative technique was also investigated.&#xD;
&#xD;
      Particularly in thoracic surgery, one lung ventilation is usually required for the surgical&#xD;
      procedure. During one-lung ventilation, the compliance of ventilated lung is decreased and&#xD;
      resistance can be increased, thereby the risk of atelectasis being increased. Furthermore,&#xD;
      after thoracic surgery, although patients were encouraged to deep breathe, it is difficult to&#xD;
      take a deep breath because of various factors. (i.e. pain, chest tube, long retracted time,&#xD;
      postoperative interstitial edema, etc.) Therefore, postoperative atelectasis is much more&#xD;
      important in patients undergoing thoracic surgery than other types of surgery.&#xD;
&#xD;
      For preventing postoperative atelectasis, the intraoperative intensity of neuromuscular&#xD;
      blockade can be a crucial factor. Because deep neuromuscular blockade provides a good lung&#xD;
      compliance during mechanical ventilation, peak inspiratory pressure can be decreased, thereby&#xD;
      reducing the risk of ventilation-induced lung injury, particularly in one lung ventilation&#xD;
      situation.However, there has been still lack of quantitative evidence that deep block is&#xD;
      superior to moderate block in the thoracic surgery with one-lung ventilation&#xD;
&#xD;
      For assessment of postoperative atelectasis, plain chest radiography may be used. However,&#xD;
      plain chest radiography can provide only a qualitative assessment of atelectasis. Computed&#xD;
      tomography can assess the whole lung by its density (HU) and enables a quantitative&#xD;
      assessment of postoperative atelectasis. Moreover, it can indicate the location of&#xD;
      atelectasis more clearly than plain chest radiography, thus provide detailed information&#xD;
      about postoperative lung state. To assess the effect of maintaining deep block and sugammadex&#xD;
      reversal on the postoperative atelectasis, using chest CT can provide a much more&#xD;
      quantitative and valuable information than conventional chest radiography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Actual">May 18, 2021</completion_date>
  <primary_completion_date type="Actual">May 14, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Atelectasis Area on Chest CT</measure>
    <time_frame>1 day after the end of surgery</time_frame>
    <description>Atelectasis on Chest CT The lung area was delineated manually. To calculate atelectasis, a region of interest was laid out that encircled the dense part of the lung, excluding large vessels. For further analysis, the lung was divided into four categories: areas with densities ranging from -1000 to -900 Hounsfield units (HU) were classified as over-aerated, from -900 to -500 HU as normally aerated, from -500 to -100 HU as poorly aerated, and from -100 to +100 HU as non-aerated (atelectasis). The proportion of non-aerated lung tissue (-100 to +100 HU) was calculated by dividing the area of the region of interest with the whole lungs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Defined as Acute Respiratory Distress Syndrome</measure>
    <time_frame>up to 7 days after the end of surgery</time_frame>
    <description>Acute respiratory distress syndrome can be defined as follows;&#xD;
Bilateral opacities not fully explained by effusions, lobar/lung collapse or nodules on chest radiograph or CT scan and Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (e.g. echocardiography) to exclude hydrostatic edema if no risk factor present and Partial pressure of pulmonary arterial oxygen / Oxygen friction &lt; 300 mmHg with positive end-expiratory pressure or continuous positive airway pressure of 5 cmH2O.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Defined as Pneumonia</measure>
    <time_frame>up to 7 days after the end of surgery</time_frame>
    <description>Pneumonia can be defined as follows;&#xD;
Two or more serial chest radiographs with at least one of the following (one radiograph is sufficient for patients with no underlying pulmonary or cardiac disease):&#xD;
new or progressive and persistent infiltrates&#xD;
consolidation&#xD;
cavitation; at least one of the following&#xD;
1) fever (&gt;38.0 C) with no other recognized cause 2) White blood cell count &lt; 4000/ml or &gt;12,000/ml 3) for adults &gt;70 yr, altered mental status with no other recognized cause; and at least two of the following&#xD;
new onset of purulent sputum or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements&#xD;
new onset or worsening cough, or dyspnea, or tachypnea&#xD;
crackles or bronchial breath sounds&#xD;
worsening gas exchange (hypoxaemia, increased oxygen requirement, increased ventilator demand).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Showing Pleural Effusion</measure>
    <time_frame>1 day after the end of surgery</time_frame>
    <description>Pleural effusion can be diagnosed on postoperative radiograph imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Showing Postoperative Desaturation</measure>
    <time_frame>up to 1 day after surgery completed</time_frame>
    <description>The number of patients showing desaturation (SpO2 &lt;95%) in room air.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Postoperative Re-intubation</measure>
    <time_frame>up to 1 day after surgery completed</time_frame>
    <description>The number of patients requiring re-intubation due to postoperative respiratory difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative Lung Compliance (ml/cmH2O)</measure>
    <time_frame>every 1 hour from the time of the tracheal intubation to the end of the skin closure.</time_frame>
    <description>Intraoperative lung compliance (ml/cmH2O) can be calculated with peak inspiratory pressure or plateau pressure, positive end-expiratory pressure and tidal volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Demographic Data</measure>
    <time_frame>on the day of admission</time_frame>
    <description>Age in years, Gender, Weight in kilograms, Height in centimeters</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">118</enrollment>
  <condition>Thoracic Surgery</condition>
  <condition>One-lung Ventilation</condition>
  <arm_group>
    <arm_group_label>Moderate block group</arm_group_label>
    <description>maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Deep block group</arm_group_label>
    <description>maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intraoperative neuromuscular blockade</intervention_name>
    <description>The intensity of intraoperative neuromuscular blockade</description>
    <arm_group_label>Deep block group</arm_group_label>
    <arm_group_label>Moderate block group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving open or thoracoscopic lobectomy, bi-lobectomy, or sleeve lobectomy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients receiving scheduled unilateral lung lobectomy.&#xD;
&#xD;
          2. Patients age ≥19&#xD;
&#xD;
          3. Patients of American Society of Anesthesiologist Physical Status 1 or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients receiving bilateral lung lobectomy&#xD;
&#xD;
          2. Patients BMI &gt; 35.0 or &lt; 18.5 kg/m2&#xD;
&#xD;
          3. Patients of contraindicated to epidural patients controlled analgesia&#xD;
&#xD;
          4. Patients with neuromuscular disease (i.e. myasthenia gravis)&#xD;
&#xD;
          5. Patients with major burn (more than 3rd degrees)&#xD;
&#xD;
          6. Patients with compromised cardiopulmonary function.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyungseok Seo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyung Hee University Hospital at Gangdong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee University Gangdong Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>05278</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Cho HC, Lee JH, Lee SC, Park SY, Rim JC, Choi SR. Use of sugammadex in lung cancer patients undergoing video-assisted thoracoscopic lobectomy. Korean J Anesthesiol. 2017 Aug;70(4):420-425. doi: 10.4097/kjae.2017.70.4.420. Epub 2017 Apr 21.</citation>
    <PMID>28794837</PMID>
  </reference>
  <reference>
    <citation>Grosse-Sundrup M, Henneman JP, Sandberg WS, Bateman BT, Uribe JV, Nguyen NT, Ehrenfeld JM, Martinez EA, Kurth T, Eikermann M. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ. 2012 Oct 15;345:e6329. doi: 10.1136/bmj.e6329.</citation>
    <PMID>23077290</PMID>
  </reference>
  <reference>
    <citation>Bulka CM, Terekhov MA, Martin BJ, Dmochowski RR, Hayes RM, Ehrenfeld JM. Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia. Anesthesiology. 2016 Oct;125(4):647-55. doi: 10.1097/ALN.0000000000001279.</citation>
    <PMID>27496656</PMID>
  </reference>
  <reference>
    <citation>Casanova J, Piñeiro P, De La Gala F, Olmedilla L, Cruz P, Duque P, Garutti I. [Deep versus moderate neuromuscular block during one-lung ventilation in lung resection surgery]. Rev Bras Anestesiol. 2017 May - Jun;67(3):288-293. doi: 10.1016/j.bjan.2017.02.005. Epub 2017 Feb 27. Portuguese.</citation>
    <PMID>28256331</PMID>
  </reference>
  <reference>
    <citation>Reinius H, Jonsson L, Gustafsson S, Sundbom M, Duvernoy O, Pelosi P, Hedenstierna G, Fredén F. Prevention of atelectasis in morbidly obese patients during general anesthesia and paralysis: a computerized tomography study. Anesthesiology. 2009 Nov;111(5):979-87. doi: 10.1097/ALN.0b013e3181b87edb.</citation>
    <PMID>19809292</PMID>
  </reference>
  <reference>
    <citation>Jammer I, Wickboldt N, Sander M, Smith A, Schultz MJ, Pelosi P, Leva B, Rhodes A, Hoeft A, Walder B, Chew MS, Pearse RM; European Society of Anaesthesiology (ESA) and the European Society of Intensive Care Medicine (ESICM); European Society of Anaesthesiology; European Society of Intensive Care Medicine. Standards for definitions and use of outcome measures for clinical effectiveness research in perioperative medicine: European Perioperative Clinical Outcome (EPCO) definitions: a statement from the ESA-ESICM joint taskforce on perioperative outcome measures. Eur J Anaesthesiol. 2015 Feb;32(2):88-105. doi: 10.1097/EJA.0000000000000118.</citation>
    <PMID>25058504</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <results_first_submitted>June 24, 2021</results_first_submitted>
  <results_first_submitted_qc>August 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 20, 2021</results_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyung Hee University Hospital at Gangdong</investigator_affiliation>
    <investigator_full_name>Hyungseok Seo</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>one-lung ventilation</keyword>
  <keyword>thoracic surgery</keyword>
  <keyword>atelectasis</keyword>
  <keyword>postoperative pulmonary complication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Atelectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/65/NCT03503565/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A patient in Deep block group declined to participate in the study after enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Moderate Block Group</title>
          <description>maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery&#xD;
intraoperative neuromuscular blockade: The intensity of intraoperative neuromuscular blockade</description>
        </group>
        <group group_id="P2">
          <title>Deep Block Group</title>
          <description>maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery&#xD;
intraoperative neuromuscular blockade: The intensity of intraoperative neuromuscular blockade</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Moderate Block Group</title>
          <description>maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery&#xD;
intraoperative neuromuscular blockade: The intensity of intraoperative neuromuscular blockade</description>
        </group>
        <group group_id="B2">
          <title>Deep Block Group</title>
          <description>maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery&#xD;
intraoperative neuromuscular blockade: The intensity of intraoperative neuromuscular blockade</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="58"/>
            <count group_id="B3" value="117"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" lower_limit="59" upper_limit="71"/>
                    <measurement group_id="B2" value="64" lower_limit="58" upper_limit="73"/>
                    <measurement group_id="B3" value="64" lower_limit="59" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="59"/>
                    <count group_id="B2" value="58"/>
                    <count group_id="B3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Preoperative abnormal chest radiography</title>
          <population>Because the number of participants only counts the people who present abnormality on preoperative chest radiography</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2"/>
                    <count group_id="B2" value="16"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Pleural effusion</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pneumothorax</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Etc.(Pulmonary edema or infiltration, atelectasis, hemothrorax)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Atelectasis Area on Chest CT</title>
        <description>Atelectasis on Chest CT The lung area was delineated manually. To calculate atelectasis, a region of interest was laid out that encircled the dense part of the lung, excluding large vessels. For further analysis, the lung was divided into four categories: areas with densities ranging from -1000 to -900 Hounsfield units (HU) were classified as over-aerated, from -900 to -500 HU as normally aerated, from -500 to -100 HU as poorly aerated, and from -100 to +100 HU as non-aerated (atelectasis). The proportion of non-aerated lung tissue (-100 to +100 HU) was calculated by dividing the area of the region of interest with the whole lungs.</description>
        <time_frame>1 day after the end of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Moderate Block Group</title>
            <description>maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery&#xD;
intraoperative neuromuscular blockade: The intensity of intraoperative neuromuscular blockade</description>
          </group>
          <group group_id="O2">
            <title>Deep Block Group</title>
            <description>maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery&#xD;
intraoperative neuromuscular blockade: The intensity of intraoperative neuromuscular blockade</description>
          </group>
        </group_list>
        <measure>
          <title>Atelectasis Area on Chest CT</title>
          <description>Atelectasis on Chest CT The lung area was delineated manually. To calculate atelectasis, a region of interest was laid out that encircled the dense part of the lung, excluding large vessels. For further analysis, the lung was divided into four categories: areas with densities ranging from -1000 to -900 Hounsfield units (HU) were classified as over-aerated, from -900 to -500 HU as normally aerated, from -500 to -100 HU as poorly aerated, and from -100 to +100 HU as non-aerated (atelectasis). The proportion of non-aerated lung tissue (-100 to +100 HU) was calculated by dividing the area of the region of interest with the whole lungs.</description>
          <units>percentage of atelectasis volume</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="0.47" upper_limit="3.20"/>
                    <measurement group_id="O2" value="1.41" lower_limit="0.24" upper_limit="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Defined as Acute Respiratory Distress Syndrome</title>
        <description>Acute respiratory distress syndrome can be defined as follows;&#xD;
Bilateral opacities not fully explained by effusions, lobar/lung collapse or nodules on chest radiograph or CT scan and Respiratory failure not fully explained by cardiac failure or fluid overload. Need objective assessment (e.g. echocardiography) to exclude hydrostatic edema if no risk factor present and Partial pressure of pulmonary arterial oxygen / Oxygen friction &lt; 300 mmHg with positive end-expiratory pressure or continuous positive airway pressure of 5 cmH2O.</description>
        <time_frame>up to 7 days after the end of surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Defined as Pneumonia</title>
        <description>Pneumonia can be defined as follows;&#xD;
Two or more serial chest radiographs with at least one of the following (one radiograph is sufficient for patients with no underlying pulmonary or cardiac disease):&#xD;
new or progressive and persistent infiltrates&#xD;
consolidation&#xD;
cavitation; at least one of the following&#xD;
1) fever (&gt;38.0 C) with no other recognized cause 2) White blood cell count &lt; 4000/ml or &gt;12,000/ml 3) for adults &gt;70 yr, altered mental status with no other recognized cause; and at least two of the following&#xD;
new onset of purulent sputum or change in character of sputum, or increased respiratory secretions, or increased suctioning requirements&#xD;
new onset or worsening cough, or dyspnea, or tachypnea&#xD;
crackles or bronchial breath sounds&#xD;
worsening gas exchange (hypoxaemia, increased oxygen requirement, increased ventilator demand).</description>
        <time_frame>up to 7 days after the end of surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Showing Pleural Effusion</title>
        <description>Pleural effusion can be diagnosed on postoperative radiograph imaging.</description>
        <time_frame>1 day after the end of surgery</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Showing Postoperative Desaturation</title>
        <description>The number of patients showing desaturation (SpO2 &lt;95%) in room air.</description>
        <time_frame>up to 1 day after surgery completed</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Postoperative Re-intubation</title>
        <description>The number of patients requiring re-intubation due to postoperative respiratory difficulty.</description>
        <time_frame>up to 1 day after surgery completed</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraoperative Lung Compliance (ml/cmH2O)</title>
        <description>Intraoperative lung compliance (ml/cmH2O) can be calculated with peak inspiratory pressure or plateau pressure, positive end-expiratory pressure and tidal volume.</description>
        <time_frame>every 1 hour from the time of the tracheal intubation to the end of the skin closure.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Demographic Data</title>
        <description>Age in years, Gender, Weight in kilograms, Height in centimeters</description>
        <time_frame>on the day of admission</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 days</time_frame>
      <desc>All-Cause Mortality, Serious, or Other (non-serious) Adverse Events were monitored/assessed, but none observed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Moderate Block Group</title>
          <description>maintaining moderate intraoperative neuromuscular blockade (TOF count 1 or 2) during surgery and reversal using sugammadex 2 mg/kg after surgery&#xD;
intraoperative neuromuscular blockade: The intensity of intraoperative neuromuscular blockade</description>
        </group>
        <group group_id="E2">
          <title>Deep Block Group</title>
          <description>maintaining deep intraoperative neuromuscular blockade (PTC 1 or 2) during surgery and reversal using sugammadex 4 mg/kg after surgery&#xD;
intraoperative neuromuscular blockade: The intensity of intraoperative neuromuscular blockade</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Hyungseok Seo</name_or_title>
      <organization>KYUNG HEE UNIVERSITY HOSPITAL AT GANGDONG</organization>
      <phone>+821029306885</phone>
      <email>seohyungseok@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

